Market Overview

UPDATE: MannKind Confirms FDA Panel Recommends Approval of AFREZZA

Related MNKD
NASDAQ Dips 1.5%; HB Fuller Shares Decline On Downbeat Results
Markets Tumble; Scholastic Posts Wider Fiscal-First Quarter Loss
MannKind: FDA Delays Afrezza Decision by Three Months (Fox Business)

MannKind Corporation (Nasdaq: MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA^® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes. If approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the United States.

"We are pleased with the Advisory Committee's approval recommendation in support of AFREZZA, and we appreciate the thoroughness of their review," said Alfred Mann, Chairman and Chief Executive Officer of MannKind Corporation. "We look forward to working with the FDA as they complete their evaluation of AFREZZA. Diabetes is a major health problem in the United States, and we are committed to bring AFREZZA to the many patients who might benefit from this novel product."

The FDA is not bound by the Advisory Committee's recommendation but will consider its guidance in reviewing the New Drug Application (NDA) that was submitted for AFREZZA. The Prescription Drug User Fee Act (PDUFA) date for the FDA to complete its review of AFREZZA is April 15, 2014.

Posted-In: News FDA

 

Related Articles (MNKD)

Around the Web, We're Loving...

Get Benzinga's Newsletters